Levetiracetam Ucb (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates synaptic transmission, decreasing excessive neuronal firing and reducing hyperexcitability that leads to seizures. The exact downstream pathways involve altered calcium‑dependent exocytosis, providing broad antiepileptic activity.

The dosing regimen for Levetiracetam Ucb is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and clinical condition. Healthcare professionals determine the appropriate infusion rate and total daily dose to achieve optimal seizure control while minimizing adverse effects.

Levetiracetam’s pregnancy category is not definitively established. It should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus. Limited data are available for breastfeeding; clinicians should weigh the benefits of treatment against possible exposure to the infant.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Levetiracetam differs from many traditional antiepileptics because it has a unique mechanism targeting SV2A and exhibits minimal enzyme‑induced drug interactions. Compared with drugs such as carbamazepine or phenytoin, it often requires less therapeutic drug monitoring and has a more favorable side‑effect profile, though individual response varies.

Levetiracetam Ucb should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The solution should be kept in its original container until use and inspected for particulate matter before administration.

Levetiracetam Ucb is given as an intravenous infusion. The rate and duration of infusion are determined by the prescriber, typically over 15 minutes to several hours, depending on the clinical scenario and patient tolerance.

Serious risks include severe allergic reactions such as Stevens‑Johnson syndrome, psychiatric disturbances like depression or suicidal thoughts, thrombocytopenia leading to bleeding, and rare cases of rhabdomyolysis. Patients should be monitored closely for any signs of these conditions, and treatment should be discontinued if they occur.

Levetiracetam Ucb is contraindicated in patients with known hypersensitivity to levetiracetam or any component of the formulation. Caution is advised for individuals with severe renal impairment, active psychiatric disorders, or those receiving live vaccines, as these conditions may increase the risk of adverse outcomes.